Compare AbCellera Biologics Inc (ABCL) vs Iris Energy Limited (IREN) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

IREN stock trades at $43.91, up 13.11% today amid speculation about a potential $22 billion Anthropic deal. The technical picture remains bearish despite the rally, with the stock missing earnings expectations for three consecutive quarters. Revenue growth appears strong with 2026 projections showing $757 million, though profitability metrics show negative ROE and ROA. Analyst consensus remains bullish with a $79.11 price target despite recent volatility.

The investment case hinges on IREN's transition from Bitcoin mining to AI infrastructure, with significant capacity expansion funded by substantial financing activities. Key risks include execution challenges in scaling operations, competitive pressure from established cloud providers, and reliance on speculative contract wins. The current valuation at 57x P/E appears stretched given negative returns on equity.